NO20062136L - Imidazopyrazintyrosin-kinaseinhibitorer - Google Patents
Imidazopyrazintyrosin-kinaseinhibitorerInfo
- Publication number
- NO20062136L NO20062136L NO20062136A NO20062136A NO20062136L NO 20062136 L NO20062136 L NO 20062136L NO 20062136 A NO20062136 A NO 20062136A NO 20062136 A NO20062136 A NO 20062136A NO 20062136 L NO20062136 L NO 20062136L
- Authority
- NO
- Norway
- Prior art keywords
- imidazopyrazintyrosin
- kinase inhibitors
- treatment
- igf
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51171203P | 2003-10-15 | 2003-10-15 | |
PCT/US2004/034219 WO2005037836A2 (en) | 2003-10-15 | 2004-10-14 | Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062136L true NO20062136L (no) | 2006-06-26 |
Family
ID=34465267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062136A NO20062136L (no) | 2003-10-15 | 2006-05-12 | Imidazopyrazintyrosin-kinaseinhibitorer |
Country Status (19)
Country | Link |
---|---|
US (2) | US7459554B2 (zh) |
EP (1) | EP1675860B1 (zh) |
JP (1) | JP4916883B2 (zh) |
KR (1) | KR100872204B1 (zh) |
CN (1) | CN1898240B (zh) |
AP (1) | AP2006003620A0 (zh) |
AR (1) | AR046337A1 (zh) |
AT (1) | ATE525377T1 (zh) |
AU (1) | AU2004282219C1 (zh) |
BR (1) | BRPI0415395A (zh) |
CA (1) | CA2542481A1 (zh) |
ES (1) | ES2372694T3 (zh) |
IL (1) | IL174948A0 (zh) |
NO (1) | NO20062136L (zh) |
RU (1) | RU2405784C2 (zh) |
SG (1) | SG132683A1 (zh) |
TW (1) | TW200530238A (zh) |
UA (1) | UA83509C2 (zh) |
WO (1) | WO2005037836A2 (zh) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2537364A1 (en) * | 2003-09-03 | 2005-03-10 | Galapagos Nv | Imidazo[1,5-a]pyridine or imidazo[1,5-a]piperidine derivatives and their use for the preparation of medicament against 5-ht2a receptor-related disorders |
AP2006003620A0 (en) * | 2003-10-15 | 2006-06-30 | Osi Pharm Inc | Imidazopyrazine tyroshine kinase inhibitors |
EP2168968B1 (en) | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
JP5055284B2 (ja) | 2005-09-20 | 2012-10-24 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | インシュリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
EP1951724B1 (en) * | 2005-11-17 | 2011-04-27 | OSI Pharmaceuticals, Inc. | FUSED BICYCLIC mTOR INHIBITORS |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
TW200730529A (en) * | 2005-12-07 | 2007-08-16 | Osi Pharm Inc | Process to prepare substituted imidazopyrazine compounds |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
JP5512975B2 (ja) | 2005-12-29 | 2014-06-04 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬 |
WO2007087395A2 (en) * | 2006-01-25 | 2007-08-02 | Osi Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
EA200870592A1 (ru) * | 2006-05-31 | 2009-08-28 | Галапагос Н.В. | Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний |
WO2008022060A2 (en) * | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
SG10201508035TA (en) * | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2008141140A1 (en) * | 2007-05-09 | 2008-11-20 | Abbott Laboratories | Condensed heterocyclic compounds as inhibitors of protein kinases |
US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
ATE527264T1 (de) * | 2007-05-09 | 2011-10-15 | Abbott Lab | Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen |
US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
WO2009038012A1 (ja) * | 2007-09-18 | 2009-03-26 | Taisho Pharmaceutical Co., Ltd. | 複素環化合物 |
AU2008307634A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2008307579A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2009091939A1 (en) | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
EP2276763A1 (en) * | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
CA2742986C (en) | 2008-11-07 | 2015-03-31 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
CN102405214A (zh) | 2009-04-20 | 2012-04-04 | Osi药物有限责任公司 | C-吡嗪-甲胺的制备 |
JP5656976B2 (ja) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
EP2475668A1 (en) * | 2009-09-10 | 2012-07-18 | Novartis AG | Ether derivatives of bicyclic heteroaryls |
WO2011060112A1 (en) | 2009-11-12 | 2011-05-19 | Osi Pharmaceuticals, Inc. | Deuterated tyrosine kinase inhibitors |
EP2528919B1 (en) * | 2010-01-28 | 2016-11-02 | University of Washington | Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
US9765037B2 (en) | 2010-01-28 | 2017-09-19 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases |
KR101661383B1 (ko) * | 2010-02-08 | 2016-09-29 | 머크 샤프 앤 도메 비.브이. | 8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물 |
CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
AR080754A1 (es) * | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
EA031737B1 (ru) | 2010-06-03 | 2019-02-28 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы |
JP2013528635A (ja) | 2010-06-17 | 2013-07-11 | ノバルティス アーゲー | ビフェニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体 |
US20130085161A1 (en) | 2010-06-17 | 2013-04-04 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2012106556A2 (en) | 2011-02-02 | 2012-08-09 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
EP2683722A1 (en) | 2011-03-08 | 2014-01-15 | Novartis AG | Fluorophenyl bicyclic heteroaryl compounds |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス,インク. | Bruton型チロシンキナーゼの阻害剤 |
EP4249076A3 (en) | 2011-07-19 | 2023-11-01 | Merck Sharp & Dohme B.V. | (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
WO2013087647A1 (en) * | 2011-12-15 | 2013-06-20 | Bayer Intellectual Property Gmbh | Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
ES2581065T3 (es) | 2012-02-23 | 2016-08-31 | Bayer Intellectual Property Gmbh | Benzotienil-pirrolotriazinas sustituidas y usos de las mismas |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CA2875986C (en) | 2012-06-04 | 2020-06-09 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
WO2014018567A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
AU2013323426A1 (en) | 2012-09-26 | 2015-04-23 | The Regents Of The University Of California | Modulation of ire1 |
EP2920180A4 (en) | 2012-11-15 | 2016-04-13 | Pharmacyclics Inc | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS |
TW201441234A (zh) * | 2013-01-23 | 2014-11-01 | Merck Sharp & Dohme | Btk抑制劑 |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | CANCER THERAPY |
JP6409055B2 (ja) | 2013-05-20 | 2018-10-17 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーションThe University Of Washington Through Its Center For Commercialization | Cdpk1の5−アミノピラゾール−4−カルボキサミド阻害剤 |
EP3036222A2 (en) * | 2013-08-23 | 2016-06-29 | Virginia Commonwealth University | Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease |
US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
CA2925124A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
WO2015057992A1 (en) | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
CA2922058A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
CN105979948A (zh) | 2013-12-05 | 2016-09-28 | 安塞塔制药公司 | Pi3k抑制剂和btk抑制剂的治疗组合 |
WO2015095099A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US9834554B2 (en) | 2013-12-20 | 2017-12-05 | Merck Sharp & Dohme Corp. | BTK inhibitors |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
CA2934989C (en) * | 2014-02-03 | 2017-08-08 | Cadila Healthcare Limited | Novel heterocyclic compounds |
US9576039B2 (en) | 2014-02-19 | 2017-02-21 | Snowflake Computing Inc. | Resource provisioning systems and methods |
EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
WO2015185998A2 (en) | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
US9949971B2 (en) | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
CA2959602A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
WO2016024228A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Btk抑制劑、pi3k抑制劑、jak-2抑制劑、及/或cdk4/6抑制劑的治療組合物 |
TW201618774A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | 使用btk抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法 |
WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2016106628A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106652A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Biarylether imidazopyrazine btk inhibitors |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106629A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106623A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
MD3265084T2 (ro) | 2015-03-03 | 2024-05-31 | Pharmacyclics Llc | Formulări farmaceutice ale inhibitorului tirozin kinazei Bruton |
RS64195B1 (sr) | 2015-07-02 | 2023-06-30 | Acerta Pharma Bv | Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
PL3402503T3 (pl) | 2016-01-13 | 2021-04-19 | Acerta Pharma B.V. | Kombinacje terapeutyczne antyfolianu oraz inhibitora btk |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
EP3548046A2 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
EA201991355A1 (ru) * | 2016-12-07 | 2019-11-29 | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
CN106831789A (zh) * | 2016-12-21 | 2017-06-13 | 南京亘泰医药技术有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
MX2020002630A (es) * | 2017-09-08 | 2020-07-20 | Beigene Ltd | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. |
JP7244504B2 (ja) * | 2017-10-18 | 2023-03-22 | インサイト・コーポレイション | PI3K-γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 |
CA3089762A1 (en) | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
BR112021003480A2 (pt) | 2018-08-29 | 2021-05-18 | Acerta Pharma B.V. | processos para a preparação de 4-{8-amino-3-[(2s)-1-(but-2-inoil)-pirrolidin-2-il]imidazo[1,5-a]-pirazin-1-il}-n-(piridin-2-il)-benzamida |
CN110964016B (zh) | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
EP3864001A1 (en) * | 2018-10-11 | 2021-08-18 | Basf As | Romatic compounds and pharmaceutical uses thereof |
JP2022525194A (ja) * | 2019-03-15 | 2022-05-11 | オールテリティ セラピューティクス リミテッド | 疾患を治療するための化合物および疾患を治療する方法 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN113620957B (zh) * | 2020-05-08 | 2022-04-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种胺甲基吡嗪类化合物的制备方法 |
US11155547B1 (en) | 2020-06-18 | 2021-10-26 | Alterity Therapeutics Limited | Compounds for and methods of treating diseases |
WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
CN114920745B (zh) * | 2022-03-28 | 2024-05-24 | 深圳海博为药业有限公司 | 一种咪唑并吡嗪类化合物及其作为igf1r抑制剂的应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
MX9304801A (es) | 1992-08-06 | 1997-06-28 | Warner Lambert Co | 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales. |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
CA2373815A1 (en) * | 1999-05-14 | 2000-11-23 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
US7087613B2 (en) * | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
GB0008368D0 (en) * | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
GB0017635D0 (en) * | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
WO2002045653A2 (en) * | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
SK9072003A3 (en) * | 2001-01-09 | 2003-11-04 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
EP1363702A4 (en) | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
JP2004528368A (ja) * | 2001-05-08 | 2004-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗egfr抗体と抗ホルモン剤を用いた組合せ療法 |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
US20030114467A1 (en) * | 2001-06-21 | 2003-06-19 | Shakespeare William C. | Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
GB0122560D0 (en) | 2001-09-19 | 2001-11-07 | Aventis Pharma Ltd | Chemical compounds |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
US20050215564A1 (en) | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
ES2280735T3 (es) * | 2002-04-16 | 2007-09-16 | Astrazeneca Ab | Terapia de combinacion para el tratamiento de cancer. |
DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
MXPA05009660A (es) | 2003-03-12 | 2005-10-20 | Pfizer Prod Inc | Derivados azabiciclicos de piridiloximetilo y bencisoxazol. |
AP2006003620A0 (en) * | 2003-10-15 | 2006-06-30 | Osi Pharm Inc | Imidazopyrazine tyroshine kinase inhibitors |
EP1694686A1 (en) * | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
EP2168968B1 (en) * | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
RU2006146612A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
WO2007075554A2 (en) * | 2005-12-19 | 2007-07-05 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
-
2004
- 2004-10-14 AP AP2006003620A patent/AP2006003620A0/xx unknown
- 2004-10-14 AR ARP040103731A patent/AR046337A1/es not_active Application Discontinuation
- 2004-10-14 EP EP04795392A patent/EP1675860B1/en active Active
- 2004-10-14 AT AT04795392T patent/ATE525377T1/de not_active IP Right Cessation
- 2004-10-14 CN CN2004800372564A patent/CN1898240B/zh not_active Expired - Fee Related
- 2004-10-14 AU AU2004282219A patent/AU2004282219C1/en not_active Ceased
- 2004-10-14 UA UAA200605222A patent/UA83509C2/uk unknown
- 2004-10-14 CA CA002542481A patent/CA2542481A1/en not_active Abandoned
- 2004-10-14 WO PCT/US2004/034219 patent/WO2005037836A2/en active Application Filing
- 2004-10-14 SG SG200703772-4A patent/SG132683A1/en unknown
- 2004-10-14 KR KR1020067009419A patent/KR100872204B1/ko not_active IP Right Cessation
- 2004-10-14 BR BRPI0415395-2A patent/BRPI0415395A/pt not_active IP Right Cessation
- 2004-10-14 ES ES04795392T patent/ES2372694T3/es active Active
- 2004-10-14 JP JP2006535379A patent/JP4916883B2/ja not_active Expired - Fee Related
- 2004-10-14 US US10/965,182 patent/US7459554B2/en active Active
- 2004-10-14 TW TW093131193A patent/TW200530238A/zh unknown
- 2004-10-14 RU RU2006116503/04A patent/RU2405784C2/ru not_active IP Right Cessation
-
2006
- 2006-04-11 IL IL174948A patent/IL174948A0/en unknown
- 2006-05-12 NO NO20062136A patent/NO20062136L/no not_active Application Discontinuation
-
2008
- 2008-07-18 US US12/175,801 patent/US20090181940A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20060086987A (ko) | 2006-08-01 |
EP1675860A2 (en) | 2006-07-05 |
RU2405784C2 (ru) | 2010-12-10 |
AP2006003620A0 (en) | 2006-06-30 |
US20080227788A9 (en) | 2008-09-18 |
IL174948A0 (en) | 2006-08-20 |
CN1898240A (zh) | 2007-01-17 |
ATE525377T1 (de) | 2011-10-15 |
AR046337A1 (es) | 2005-12-07 |
AU2004282219B2 (en) | 2009-07-30 |
RU2006116503A (ru) | 2007-11-20 |
US20090181940A1 (en) | 2009-07-16 |
CN1898240B (zh) | 2011-08-03 |
JP2007509060A (ja) | 2007-04-12 |
US20060084654A1 (en) | 2006-04-20 |
WO2005037836A2 (en) | 2005-04-28 |
AU2004282219C1 (en) | 2009-12-17 |
EP1675860B1 (en) | 2011-09-21 |
UA83509C2 (en) | 2008-07-25 |
CA2542481A1 (en) | 2005-04-28 |
SG132683A1 (en) | 2007-06-28 |
US7459554B2 (en) | 2008-12-02 |
TW200530238A (en) | 2005-09-16 |
JP4916883B2 (ja) | 2012-04-18 |
BRPI0415395A (pt) | 2006-12-12 |
WO2005037836A3 (en) | 2005-06-09 |
KR100872204B1 (ko) | 2008-12-09 |
AU2004282219A1 (en) | 2005-04-28 |
ES2372694T3 (es) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062136L (no) | Imidazopyrazintyrosin-kinaseinhibitorer | |
NO20070917L (no) | Imidazotriaziner som protein-kinaseinhibitorer | |
NO20084845L (no) | 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20055565L (no) | Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO) | |
NO20084872L (no) | 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig | |
NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
NO20051263L (no) | Ny anvendelse av benzotiazolderivater | |
NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
DE60315674D1 (de) | Neue imidazopyridine und ihre verwendung | |
NO20090025L (no) | Pyrrolotriazinkinaseinhibitorer | |
NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
NO20053144L (no) | Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler. | |
NO20073465L (no) | Benzotiazol-derivater | |
NO20076066L (no) | Oksadiazolderivater som DGAT-inhibitorer | |
NO20090580L (no) | Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer | |
NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
WO2004031401A3 (en) | Novel tyrosine kinases inhibitors | |
WO2004001059A3 (en) | Heterocyclic inhibitors of kinases | |
NO20055887L (no) | Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer | |
NO20091590L (no) | Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer | |
WO2007007919A3 (en) | Heterocyclic janus kinase 3 inhibitors | |
NO20072399L (no) | Nye pyrrolo[3,2-d]pyrimidin-4-o-derivater og deres anvendelse i terapi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |